Philip Morris International Inc. $(PMI)$ presented scientific evidence to the U.S. Food and Drug Administration's (FDA) Tobacco Products Scientific Advisory Committee (TPSAC) as part of the FDA's review process for a Modified Risk Tobacco Product (MRTP) designation for ZYN nicotine pouch products. In January 2025, ZYN became the first nicotine pouch product authorized for marketing by the FDA. The MRTP designation, if granted, would allow PMI to communicate that switching completely to ZYN reduces the risk of several smoking-related diseases for adult smokers. The FDA noted that the proposed modified risk claim is scientifically accurate and that youth nicotine pouch use prevalence is currently relatively low. A decision by the FDA on the MRTP designation is pending.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Philip Morris International Inc. published the original content used to generate this news brief on January 23, 2026, and is solely responsible for the information contained therein.